Evidence for an autoimmune pathogenesis of vitiligo

Pigment Cell Research

Volumn 16, Issue 2, 2003, Pages 90-100

  Ongenae, Katia ^a   Van Geel, Nanny ^a   Naeyaert, Jean Marie ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Autoimmunity; Pathogenesis; Vitiligo

Indexed keywords

AUTOANTIBODY;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; DISEASE ASSOCIATION; EPIDERMIS; HISTOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; NONHUMAN; PATHOGENESIS; REVIEW; T LYMPHOCYTE; VITILIGO;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, CELLULAR; MELANOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VITILIGO;

ANIMALIA;

EID: 0037648525     PISSN: 08935785     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0749.2003.00023.x     Document Type: Review

References (145)

1. Njoo MD, Westerhof W. Vitiligo: Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167-181
2. Kemp EH, Waterman EA, Weetman AP. Autoimmune aspects of vitiligo. Autoimmunity 2001;34:65-77
3. Ortonne JP, Bose SK. Vitiligo: where do we stand. Pigment Cell Res 1993;6:61-72
4. Castenet J, Ortonne JP. Pathophysiology of vitiligo. Clin Dermatol 1997;15:845-851
5. Norris DA, Horikawa T, Morelli JG. Melanocyte destruction and repopulation in vitiligo. Pigment Cell Res 1994;7:193-203
6. Le Poole IC, Das PK, van den Wijngaard RMJGJ, Bos JD, Westerhof W. Review of ethiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993;2:145-153
7. Schallreuter KU, Lemke R, Brandt O, Schwartz R, Westhofen M, Montz R, Berger J. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology 1994;188:269-275
8. Grimes PE, Halder MH, Jones C, Chakrabarti SG, Enterline J, Minus HR, Kenney JA Jr. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983;119:300-303
9. Hegedüs L, Heidenheim M, Gervil M, Hjalgrim H, Hoier-Madsen M. High frequency of thyroid dysfunction in patients with vitiligo. Acta Derm Venereol 1994;74:120-123
10. Betterle C, Caretto A, De Zio A, Pedini B, Veller-Fornasa C, Cecchetto A, Accordi F, Peserico A. Incidence and significance of organ-specific autoimmune disorders (clinical, latent, or only autoantibodies) in patients with vitiligo. Dermatologica 1985;171:419-423
11. Shong YK, Kim JA. Vitiligo in autoimmune thyroid disease. Thyroidology 1991;3:89-91
12. Barnadas MA, Rodriguez-Arias JM, Alomar A. Subcutaneous sarcoïdosis associated with vitiligo, pernicious anemia and autoimmune thyro. Clin Exp Dermatol 2000;25:55-56
13. Gould IM, Gray RS, Urbaniak SJ, Elton RA, Duncan LJP. Vitiligo in diabetes mellitus. Br J Dermatol 1985;113:153-155
14. Mulligan TM, Sowers JR. Hyperpigmentation, vitiligo and Addison's disease. Cutis 1985;36:317-318, 322
15. Mihailova D, Grigorova R, Vassileva B, Mladenova G, Ivanova N, Stephanov S, Lissitchky K, Dimova E. Autoimmune thyroid disorders in juvenile chronic arthritis and systemic lupus erythematosus. Adv Exp Med Biol 1999;455:55-60
16. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol 1996;35:22-27
17. Tan RS. Ulcerative colitis, myastenia gravis, atypical lichen planus, alopecia areata, vitiligo. Proc R Soc Med 1974;67:195-196
18. Howitz J, Schwartz M. Vitiligo, achlorhydria, and pernicious anemia. Lancet 1971;26:1331-1334
19. Abraham Z, Rozenbaum M, Glück Z, Feuerman E, Lahat N, Kinarty A. Vitiligo, rheumatoid arthritis and pernicious anemia. J Dermatol 1993;20:418-423
20. Terunuma A, Watabe A, Kato T, Tagami H. Coexistence of vitiligo and sarcoidosis in a patient with circulating autoantibodies. Int J Dermatol 2000;39:550-559
21. Sacher M, Blumel P, Thaler H, Manns M. Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies. J Hepatol 1990;10:364-369
22. Okada T, Sakamoto T, Ishibashi T, Inomata H. Vitiligo in Vogt-Koyanagi-Harada disease, immunohistochemical analysis of inflammatory site. Graefes Arch Clin Exp Ophtalmol 1996;234:359-363
23. Tsuruta D, Hamada T, Teramae H, Mito H, Ishii M. Inflammatory vitiligo in Vogt-Koyanagi-Harada disease. J Am Acad Dermatol 2001;44:129-131
24. Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990;322:1829-1836
25. Klisnick A, Schmidt J, Dupond JL, Bouchou K, Rousset H, Thieblot P, Humbert P, Vidal E, Aumaître O. Le vitiligo au cours des syndromes auto-immuns multiples: étude retrospective de 11 observations et revue de la litérature. Rev Méd Interne 1998;19:348-352
26. Kubota A, Komiyama Tanigawa A, Hasegawa O. Frequency and clinical correlates of vitiligo in myasthenia gravis. J Neurol 1997;244:388-389
27. Dhar S, Malakar S, Dhar S. Colocalization of vitiligo and psoriasis in a 9-year-old boy. Pediatr Dermatol 1998;15:242-243
28. Hwang SM, Ahn SK, Choi EH. Psoriasis occurring in amelanotic lesions. J Dermatol 1998;25:66-67
29. Rubisz-Brzezinska J, Büchner SA, Itin P. Vitiligo associated with lichen planus. Is there a pathogenic relationship? Dermatology 1996;192:176-178
30. Anstey A, Marks R. Colocalization of lichen planus and vitiligo. Br J Dermatol 1993;128:103-104
31. Bouloc A, Grange F, Delfau-Larue MH, Dieng MT, Tortel MC, Avril MF, Revuz J, Bagot M, Wechsler J. Leucoderma associated with flares of erythrodermic cutaneous T-cell lymphomas: four cases. Br J Dermatol 2000;143:832-836
32. Lorini R, Orecchia G, Martinetti M, Dugoujon JM, Cuccia M. Autoimmunity in vitiligo: relationship with HLA Gm and Km polymorphisms. Autoimmunity 1992;11:255-260
33. Bystryn JC. Serum antibodies in vitiligo patients. Clin Dermatol 1989;7:136-145
34. Kao CH, Yu HS. Comparison of the effect of 8-Methoxypsoralen (8-MOP) plus UVA (PUVA) on human melanocytes in vitiligo vulgaris and in vitro. J Invest Dermatol 1992;98:734-740
35. Duthie MS, Kimber I, Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol 1999;140:995-1009
36. Abdel-Naser MB, Hann SK, Bystryn JC. Oral psoralen with UVA therapy releases circulating growth factors that stimulate cell proliferation. Arch Dermatol 1997;133:1530-1533
37. Fitzpatrick TB. Mechanisms of phototherapy of vitiligo. Arch Dermatol 1997;133:1591-1592
38. Viac J, Goujon C, Misery L, Staniek V, Faure M, Schmitt D, Claudy A. Effect of UVB 311 nm irradiation on normal human skin. Photodermatol Photoimmunol Photomed 1997;13:103-108
39. Krutmann J, Morita A. Mechanisms of ultraviolet (UV) B and phototherapy. J Invest Dermatol Symp Proc 1999;4:70-72
40. Halder RM, Young CM. New and emerging therapies for vitiligo. Dermatol Clin 2000;18:79-89
41. Hann SK, Kim HI, Im S, Park YK, Cui J, Bystryn JC. The change of melanocyte cytotoxicity after systemic steroid treatment in vitiligo patients. J Dermatol Sci 1993;6:201-205
42. Lamont SJ, Smyth JR. Effect of bursectomy on development of a spontaneous postnatal amelanosis. Clin Immunol Immunopath 1981;21:407-411
43. Pardue SL, Fite KV, Bengston L, Lamont SJ, Boyle ML, Smyth JR. Enhanced integumental and ocular amelanosis following the termination of cyclosporin administration. J Invest Dermatol 1987;88:758-761
44. Gupta AK, Ellis CN, Nickoloff BJ et al. Oral cyclosporin in the treatment of inflammatory and noninflammatory dermatoses. Arch Dermatol 1990;126:339-350
45. Stutz JA, Ellis CN. Dermatological uses of cyclosporin. Management of dermatoses other than psoriasis and atopic dermatitis. Clin Drug Invest 1995;10:22-35
46. Simsek H, Savas C, Akkiz H, Telatar H. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection. Dermatology 1996;193:65-66
47. Nourik K, Busso M, Machler BC. Vitiligo associated with alpha-interferon in a patient with chronic active hepatitis C. Cutis 1997;60:289-290
48. Neumeister P, Strunk D, Apfelbeck U, Sill H, Linkesch W. Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Lancet 2000;15:1334-1335
49. Alajlan A, Alfadley A, Pedersen KT. Transfer of vitiligo after allogeneic bone marrow transplantation. J Am Acad Dermatol 2002;46:606-610
50. Au WY, Yeung CK, Chan HH, Lie AK. Generalized vitiligo after lymphocyte infusion for relapsed leukaemia. Br J Dermatol 2001;145:1015-1017
51. Mimouni D, David M, Feinmesser M, Coire CI, Hodak E. Vitiligo-like leucoderma during photochemotherapy for mycosis fungoides. Br J Dermatol 2001;145:1008-1014
52. Naughton GK, Eisinger M, Bystryn JC. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983;81:540-542
53. Hertz KC, Gazze LA, Kirckpatrick CH, Katz SI. Autoimmune vitiligo. Detection of antibodies to melanin-producing cells. N Engl J Med 1977;297:634-637
54. Yu HS, Kao CH, Yu CL. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993;100:823-828
55. Hann SK, Shin HK, Park SH, Reynolds SR, Bystryn JC. Detection of antibodies to melanocytes in vitiligo by western blotting. Yonsei Med J 1996;37:365-370
56. Fishman P, Azizi E, Shoenfeld Y, Sredni B, Yesheskel G, Ferrone S, Zigelman R, Chaitchik S, Floro S, Djaldetti M. Vitiligo autoantibodies are effective against melanoma. Cancer 1993;72:2365-2369
57. Cui J, Arita Y, Bystryn JC. Cytolytic antibodies to melanocytes in vitiligo. J Invest Dermatol 1993;100:812-815
58. Norris DA, Capin L, Muglia JJ, Osborn RL, Zerbe GO, Bystryn JC, Tonnesen MG. Enhanced susceptibility of melanocytes to different immunologic effector mechanisms in vitro: potential mechanisms for postinflammatory hypopigmentation and vitiligo. Pigm Cell Res 1988;1 (Suppl.):113-123
59. Gilhar A, Zelickson B, Ulman Y, Etzioni A. In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. J Invest Dcrmatol 1995;105:683-686
60. Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991;97:1078-1080
61. Xie P, Geoghegan WD, Jordan RE. Vitiligo autoantibodies, studies of subclass distribution and complement activation (Abstract). J Invest Dermatol 1991;96:627
62. Uda H, Takei M, Mishima Y. Immunopathology of vitiligo vulgaris, Sutton's leukoderma and melanoma-associated vitiligo in relation to steroid effects. II. The IgG and C3 deposits in the skin. J Cut Pathol 1984;11:114-124
63. Aronson PJ, Hashimoto K. Association of IgA anti-melanoma antibodies in the sera of vitiligo patients with active disease (Abstract). J Invest Dermatol 1987;88:475
64. Cui J, Arita Y, Bystryn JP. Characterization of vitiligo antigens. Pigment Cell Res 1995;8:53-59
65. Cui J, Harning R, Henn M, Bystryn JP. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992;98:162-165
66. Park YK, Kim NS, Hann SK, Im S. Identification of autoantibody to melanocytes and characterization of vitiligo antigen in vitiligo patients. J Dermatol Sci 1996;11:111-120
67. Hann SK, Koo SW, Kim JB, Park YK. Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by western blot analysis. J Dermatol 1996;23:100-103
68. Rocha IM, Oliveira LJ, De Castro LC, de Araujo Pereira LI, Chaul A, Guerra JG, Silvestre MC, Batista KM, Pereira FA, Gomide MA, Guillo LA. Recognition of melanoma cell antigens with antibodies present from patients with vitiligo. Int J Dermatol 2000;39:840-843
69. Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN. A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 1996;2:1837-1842
70. Song YH, Connor E, Li Y, Zorovich B, Balducci P. Maclaren: The role of tyrosinase in autoimmune vitiligo. Lancet 1994;344:1049-1059
71. Baharav E, Merimski O, Shoenfeld Y, Zigelman R, Gilbrud B, Yecheskel G, Youini P, Fishman P. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996;105:84-88
72. Okamoto T, Irie RF, Fujii S, Huang SKS, Nizze AJ, Morton DL, Hoon DSB. Anti-tyrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998;111:1034-1039
73. Xie Z, Chen D, Jiao D, Bystryn JC. Vitiligo antibodies are not directed to tyrosinase. Arch Dermatol 1999;135:417-422
74. Kemp EH, Gawkrodger DJ, MacNeil S, Watson PF, Weetman AP. Detection of tyrosinase autoantibodies in patients with vitiligo using 35 S-labeled recombinant human tyrosinase in a radioimmunoassay. J Invest Dermatol 1997;109:69-73
75. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Immunoprecipitation of melanogenic enzyme autoantigens with vitiligo sera: evidence for cross-reactive autoantibodies to tyrosinase and tyrosinase-related protein-2 (TRP-2). Clin Exp Immunol 1997;109:495-500
76. Kemp EH, Waterman EA, Gawkrodger DJ, Watson PF, Weetman A. Auto-antibodies to tyrosinase-related protein-1 in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998;139:798-805
77. Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Autoantibodies to human melanocyte-specific protein Pme117 in the sera of vitiligo patients: a sensitive and quantitative radioimmunoassay. Clin Exp Immunol 1998;114:333-338
78. Waterman EA, Kemp EH, Gawkrodger DJ, Watson PF, Weetman AP. Antoantibodies in vitiligo patients are not directed to the melanocyte differentiationantigen MelanA/MART1. Clin Exp Immunol 2002;129:527-532
79. Kemp EH, Waterman EA, Hawes BE, O'Neill K, Gottumukkala RVSRK, Gawkrodger DJ, Weetman AP, Watson PF. The melanin-concentrating hormone receptor 1, a novel target of autoantibody responses in vitiligo. J Clin Invest 2002;109:923-930
80. Hedstrand H, Ekwall O, Olsson MJ, Landgren E, Kemp EH, Weetman AP, Perheentupa J, Husebye E, Gustafsson J, Betterle C, Kampe O, Rorsman F. The transcription factors SOX9 and SOX10 are vitiligo autoantibodies in autoimmune polyendocrine syndrome type I. J Bioch Chem 2001;276:35390-35395
81. Naughton GK, Reggiardo MD, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986;15:978-981
82. Moellman GE, Krass P, Halaban R, Kuklinska E, Lerner AB. On the subject of serum antibodies to melanocytes in vitiligo (Abstract). J Invest Dermatol 1985;84:333
83. Hara I, Takechi Y, Houghton AN. Implicating a role for immunerecognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 1995;182:1609-1614
84. Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patient's sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988;90:783-789
85. Van Den Wijngaard RM, Asghar SS, Pijnenborg AC, Tigges AJ, Westerhof W, Das PK. Aberrant expression of complement regulatory proteins, membrane cofactor protein and decay accelerating factor, in the involved epidermis of patients with vitiligo. Br J Dermatol 2002;146:80-87
86. Yi YL, Yu CH, Yu HS. IgG anti-melanocyte antibodies purified from patients with active vitiligo induce HLA-Dr and intercellular adhesion molecule-1 expression and an increase in interleukin-8 realease by melanocytes. J Invest Dermatol 2000;115:969-973
87. Abdel Naser MB, Krüger-Krasagakes S, Krasagakis K, Gollnick H, Orfanos CE. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994;7:1-8
88. Uz-Zaman T, Begum S, Waheed MA. In vitro assessment of T lymphocyte functioning in vitiligo. Acta Derm Venereol 1992;72:266-267
89. Hann SK, Park YK, Chung KY, Kim HI, Im S, Won JH. Peripheral lymphocyte imbalance in Koreans with active vitiligo. Int J Dermatol 1993;32:286-289
90. D'Amelio R, Frati C, Fattorossi A, Aiuti F. Peripheral T-cell subset imbalance in patients with vitiligo and their apparently healthy first-degree relatives. Ann Allergy 1990;65:143-145
91. Mahmoud F, Abul H, Al-Saleh Q, Haines D, Burleson J, Morgan G. Peripheral T cell activation in non-segmental vitiligo. J Dermatol 1998;25:637-640
92. Abdel Naser MB, Ludwig WD, Gollnick H, Orfanos CE. Nonsegmental vitiligo: decrease of the CD45RA+ T-cell subset an evidence for peripheral T-cell activation. Int J Dermatol 1992;31:321-325
93. Al Fouzan A, al-Arbash M, Fouad F, Kaaba SA, Mousa MA, al-Harbi SA. Study of HLA class I/II and T lymphocyte subsets in Kuwaiti vitiligo patients. Eur J Immunogenet 1995;22:209-213
94. Mozzanica N, Frigerio U, Negri M, Tadini GL, Villa ML, Mantovani M, Finzi AF. Circadian rhythm of natural killer cell activity in vitiligo. J Am Acad Dermatol 1989;20:591-596
95. Mozzanica N, Frigerio U, Finzi AF, Cattaneo A, Negri M, Scaglione F, Fraschini F, Foppa S. T cell subpopulations in vitiligo: a chronobiologic study. J Am Acad Dermatol 1990;22:223-230
96. Mozzanica N, Villa ML, Foppa S, Vignati G, Cattaneo A, Diotti R, Finzi AF. Plasma α-melanocyte-stimulating hormone, β-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992;26:693-700
97. Durham-Pierre DG, Walters CS, Halder RM, Pham HN, Vanderpool EA. Natural killer cell and lymphokine activated killer cell activity against melanocytes in vitiligo. J Am Acad Dermatol 1995;33:26-30
98. Hann SK, Park YK, Lee KG, Choi EH, Im S. Epidermal changes in active vitiligo. J Dermatol 1992;19:217-222
99. Moellmann G, Klein-Angerer S, Scollay DA, Nordlund JJ, Lerner AB. Extracellular granular material and degeneration of keratinocytes in the normally pigmented epidermis of patients with vitiligo. J Invest Dermatol 1982;97:321-330
100. Le Poole IC, van den Wijngaard RMJGJ, Westerhof W, Dutrieux R, Das PK. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993;100:816-822
101. Le Poole IC, van den Wijngaard MJGJ, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996;148:1219-1228
102. Abdel Naser MB. Evidence for primary involvement of keratinocytes in vitiligo (Abstract). Arch Dermatol Res 1991;283:47
103. Al Badri AM. An immunohistochemical study of cutaneous lymphocytes in vitiligo. J Pathol 1993;170:149-155
104. Al Badri AM. Abnormal expression of MHC class II and ICAM-I by melanocytes in vitiligo. J Pathol 1993;169:203-206
105. Okada T, Sakamoto T, Ishibashi T, Inomata H. Vitiligo in Vogt-Koyanagi-Harada disease: immunohistological analysis of inflammatory site. Graefe's Arch Clin Exp Ophtalmol 1996;234:359-363
106. Horn TD. Analysis of the lymphocytic infiltrate in a case of vitiligo. Am J Dermatopathol 1997;19:400-402
107. Von Den Driesch P, Fartasch M, Hornstein OP. Chronic actinic dermatitis with vitiligo-like depigmentation. Clin Exp Dermatol 1992;17:38-43
108. Abdel Naser MB, Ludwig WD, Gollnick H, Orfanos CE. Non segmental vitiligo: decrease of the CD45RA+ T-cell subset an evidence for peripheral T-cell activation. Int J Dermatol 1992;31:321-325
109. Mahmoud F, Abul H, Haines D, Al-Saleh C, Khajeji M, Whaley K. Decreased total numbers of peripheral blood lymphocytes with elevated percentages of CD4+CD45RO+ and CD4+ CD25+ of T helper cells in non-segmental vitiligo. J Dermatol 2002;29:68-73
110. Yu HS, Chang KL, Yu CL, Li HF, Wu MT, Wu CS, Wu CS. Alterations in IL-6, IL-8, GM-CSF, TNF-α and IFN-γ release by peripheral mononuclear cells in patients with active vitiligo. J Invest Dermatol 1997;108:527-529
111. Honda Y, Okubo Y, Koga M. Relationship between levels of soluble interleukin-2 receptors and the types and activity of vitiligo. J Dermatol 1997;24:561-563
112. Yeo UC, Yang YS, Park KB, Sung HT, Jung SY, Lee ES, Shin MH. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci 1999;19:182-188
113. Caixa T, Hongwen F, Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci 1999;21:59-62
114. Goudie RB, Soukoup M, Dagg JH. Hypothesis: symmetrical cutaneous lymphoma. Lancet 1990;335:316-318
115. Van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, Tigges B, Westerhof W, Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000;80:1299-1309
116. Van den Wijngaard R, Wankowicz-Kalinska A, Pals S, Weening J, Das P. Autoimmune melanocyte destruction in vitiligo. Lab Invest 2001;81:1061-1067
117. Ahn SK, Choi EH, Lee SH, Won JH, Hann SK, Park YK. Immunohistochemical studies from vitiligo-comparison between active and inactive lesions. Yonsei Med J 1994;35:404-410
118. Le Poole IC, Mutis T, van den Wijngaard RM, Westerhof W, Ottenhoff T, de Vries RR, Das PK. A novel antigen-presenting function of melanocytes and its possible relationship to hypopigmenatry disorders. J Immunol 1993;151:7284-7292
119. Das PK, Van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C. A symbiotic concept of autoimmunity and tumour immunity: lessons from vitiligo. Trends Immunol 2001;22:130-136
120. Faccheti F, de Wolf-Peeters C, de Greef H, Desment VJ. Langerhans cells in various benign and malignant pigment-cell lesions of the skin. Arch Dermatol Res 1984;276:283-287
121. Westerhof W, Groot I, Krieg SR, Bos JD, Cormane RH. Langerhans cell population studies with OKT6 and HLA-DR monoclonal antibodies in vitiligo patients treated with oral phenylalanine loading and UVA irradiation. Acta Derm Venereol 1986;66:259-274
122. Hatchome N, Aiba S, Kato T, Torinuki W, Tagami H. Possible functional impairment of Langerhans cells in vitiliginous skin. Arch Dermatol 1987;123:51-54
123. Claudy AL, Rouchouse B. Langerhans cell and vitiligo: quantitative study of T6 and HLA-DR antigen-expressing cells. Acta Derm Venereol 1984;64:334-336
124. Marganian H, Grimes P, Peng SK, Sun N, Kelly AP. Degenerative changes of melanocytes, keratinocytes and Langerhans' cells in vitiligo (Abstract). Faseb J 1990;4:4
125. Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in non-segmental type vitiligo. J Dermatol 1990;17:287-296
126. Jimbow T, Mishima Y. UV- and steroïd resistant, antigenic markerpositive Langerhans cells increased in acute progressive phase vitiligo during PUVA and steroïd therapy (Abstract). J Invest Dermatol 1989;92:453
127. Gilhar A, Aizen E, Ohana N, Etzioni A. Vitiliginous versus pigmented skin response to intradermal administration of interferon gamma. Arch Dermatol 1993;129:600-604
128. Bergstresser PR. Langerhans' cells in vitiligo. Arch Dermatol 1987;123:1267
129. Ogg GS, Dunbar PR, Romero P, Chen JL, Cerundulo V. High frequency of skin-homing melanocyte-specific cytotoxie T lymphocytes in autoimmune vitiligo. J Exp Med 1998;188:1203-1208
130. Palermo B, Campanelli R, Garbelli S, Mantovani S, Lantelme E, Brazelli V, Ardigo M, Borroni G, Martinetti M, Badulli C, Necker A, Giachino C. Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. J Invest Dermatol 2001;117:326-332
131. Lang KS, Caroli CC, Muhm D, Wernet D, Moris Aschittek B, Knauss-Scherwitz E, Stevanovic S, Rammensee HG, Garbe C. HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1. J Invest Dermatol 2001;116:891-897
132. Le Gal FA, Avril MF, Bosq J, Lefebvre P, Deschemin JC, Andrieu M, Dore MX, Guillet JG. Direct evidence to support the role of antigen-specific CD8+ T cells in melanoma-associated vitiligo. J Invest Dermatol 2001;117:1464-1470
133. Becker JC, Guldberg P, Zeuthen J, Bröcker EB, Thor Straten P. Accumulation of identical T cells in melanoma and vitiligo-like leukoderma. J Invest Dermatol 1999;113:1033-1038
134. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MD, Riddell SR, Greenberg PD. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell mediated vitiligo. J Exp Med 2001;192:1637-1643
135. Jager E, Maeurer M, Hohn H, Korbach Jager D, Zidiniakis Z, Bakhshandeh-Bath A, Orth J, Neukrich C, Necker A, Reichert TE, Knuth A. Clonal expansion of Melan-A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int J Cancer 2000;86:538-547
136. Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G. Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas-Ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 1998;161:1220-1230
137. Zarour HM, Kirkwood JM, Kierstead LS, Herr W, Brusic V, Slinguff CL, Sidney J, Sette A, Storkus WJ. Melan-A/MART-1 (51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 2000;97:400-405
138. Wang S, Bartido S, Yang G, Qin J, Moroi Y, Panageas KS, Lewis JJ, Houghton AN. A role for melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. J Immunol 1999;163:5820-5826
139. Huang CL, Nordlund JJ, Boissy R, Vitiligo. A manifestation of apoptosis. Am J Clin Dermatol 2002;3:301-308
140. Moretti S, Spallanzani A, Amato L, Hautmann G, Gallerani I, Fabiani M, Fabbri P. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. Pigment Cell Res 2002;15:87-92
141. Musette P, Bachelez H, Flageul B, Delarbre C, Kourilsky P, Dubertret L, Gachelin G. Immune-mediated destruction of melanocytes in halo nevi is associated with the local expansion of a limited number of T cell clones. J Immunol 1999;162:1789-1794
142. Boisseau-Garsaud AM, Pont F, Quist D, Verna A. Vitiligo et apoptose (Abstract). Ann Dermatol Venereol 2001;128:3S281
143. Boissy RE. Histology of vitiliginous skin. In: Hann SK Nordlund J, eds. Vitiligo: monograph on the basic and clinical science. Oxford: Blackwell Science Ltd, 2000: 23-34.
144. Bowne WB, Srinivasan R, Wolchok JD, Hawkins WG, Blachere NE, Dyall R, Lewis JJ, Houghton AN. Coupling and uncoupling of tumor immunity and autoimmunity. J Exp Med 1999;190:1717-1722
145. Van den Wijngaard RM, Aten J, Scheepmaker A, Le Poole IC, Tigges AJ, Westerhof W, Das PK. Expression and modulation of apoptosis regulatory molecules in human melanocytes: significance in vitiligo. Br J Dermatol 2000;143:573-581